About UDP-N-acetylglucosamine transferase subunit ALG14
UDP-N-acetylglucosamine transferase subunit ALG14 (ALG14) is a protein
from Homo sapiens identified by UniProt accession
Q96F25, 216 residues long.
MolForge cross-references it against 0 known binders and
58 disease associations.
Target properties
| Protein name | UDP-N-acetylglucosamine transferase subunit ALG14 |
|---|
| UniProt accession | Q96F25 |
|---|
| Gene | ALG14 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 216 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (58)
Diseases linked to this target (Open Targets).
- myopathy, epilepsy, and progressive cerebral atrophy · score 0.59
- congenital myasthenic syndrome 15 · score 0.58
- neurodegenerative disease · score 0.53
- intellectual developmental disorder with epilepsy, behavioral abnormalities, and coarse facies · score 0.49
- Congenital myasthenic syndromes · score 0.46
- congenital myasthenic syndromes with glycosylation defect · score 0.37
- congenital myasthenic syndrome · score 0.37
- fatty acid measurement · score 0.24
- genetic disorder · score 0.19
- adolescent idiopathic scoliosis · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96F25-F1 | alphafold | PREDICTED | 90.94 | — |
Amino-acid sequence (216 residues)
MVCVLVLAAA AGAVAVFLIL RIWVVLRSMD VTPRESLSIL VVAGSGGHTT EILRLLGSLS NAYSPRHYVI ADTDEMSANK INSFELDRAD RDPSNMYTKY YIHRIPRSRE VQQSWPSTVF TTLHSMWLSF PLIHRVKPDL VLCNGPGTCV PICVSALLLG ILGIKKVIIV YVESICRVET LSMSGKILFH LSDYFIVQWP ALKEKYPKSV YLGRIV
Explore UDP-N-acetylglucosamine transferase subunit ALG14 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets